At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 80 enrolled
Drug / intervention
0.003% AR-15512 ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b Study to Investigate the Effect of 0.003% AR-15512 on the Ocular Surface Characteristics of Subjects With Dry Eye Disease
In Brief
A Phase 3 clinical trial evaluating 0.003% AR-15512 ophthalmic solution and Artificial Tears for Dry Eye Disease. Completed, enrolled 80 participants across 4 sites.
Detailed Summary
The purpose of this study is to evaluate the effect of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) on ocular surface characteristics of subjects with dry eye disease (DED).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20252026
First PostedAug 2024
Enrollment StartOct 2024
Primary CompletionMar 2025
TodayJul 2026
First PostedAug 9, 2024
Enrollment StartOct 8, 2024
Primary CompletionMar 21, 2025
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 1.9 years ago
Interventions
0.003% AR-15512 ophthalmic solutiondrug
Investigational ophthalmic solution administered via topical instillation
Artificial Tearsother
Commercially available, preservative-free lubricant eye drops administered via topical instillation